TY - JOUR
T1 - Efficacy of omega-3 for vasomotor symptoms treatment
T2 - A randomized controlled trial
AU - Cohen, Lee S.
AU - Joffe, Hadine
AU - Guthrie, Katherine A.
AU - Ensrud, Kristine E.
AU - Freeman, Marlene
AU - Carpenter, Janet S.
AU - Learman, Lee A.
AU - Newton, Katherine M.
AU - Reed, Susan D.
AU - Manson, Joann E.
AU - Sternfeld, Barbara
AU - Caan, Bette
AU - Freeman, Ellen W.
AU - Lacroix, Andrea Z.
AU - Tinker, Lesley F.
AU - Booth-Laforce, Cathryn
AU - Larson, Joseph C.
AU - Anderson, Garnet L.
PY - 2014/4
Y1 - 2014/4
N2 - OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI,-3.0 to-1.9) did not differ significantly from that with placebo (-2.7; 95% CI,-3.3 to-2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI,-0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI,-0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.
AB - OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI,-3.0 to-1.9) did not differ significantly from that with placebo (-2.7; 95% CI,-3.3 to-2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI,-0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI,-0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.
KW - Clinical Trials Network
KW - Fish oils
KW - Hot flashes
KW - Menopause
KW - Omega-3
KW - Vasomotor symptoms
UR - http://www.scopus.com/inward/record.url?scp=84897413811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897413811&partnerID=8YFLogxK
U2 - 10.1097/GME.0b013e31829e40b8
DO - 10.1097/GME.0b013e31829e40b8
M3 - Article
C2 - 23982113
AN - SCOPUS:84897413811
SN - 1072-3714
VL - 21
SP - 347
EP - 354
JO - Menopause
JF - Menopause
IS - 4
ER -